TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel therapeutics to treat diseases. Our technology identifies small molecules that promote the interaction between two proteins which alters the fate or function of the disease target protein. One such application aims to activate the innate protein degradation machinery to destroy the disease target. These innovative “molecular glues” allow us to treat diseases in entirely new ways, by pursuing highly relevant disease targets that have long been considered undruggable or are inadequately addressed.